Hawaii Isotope Technology (HIT) has made a groundbreaking move in the medical technology sector with the official opening of its new, $20 million facility dedicated to cancer imaging drug production. Located in Kapolei, Hawaii, this state-of-the-art facility significantly expands the company's capabilities in providing essential medical isotopes for diagnostic imaging, marking a substantial investment in Hawaii's growing biotechnology sector.

The construction of this facility spanned 28 months, highlighting the company's commitment to advancing medical technology and improving patient care through innovative isotope solutions. A key component of the facility is an 80,000-pound cyclotron, a particle accelerator crucial for producing radioactive isotopes. This cyclotron was specially imported from Sweden, showcasing the advanced technology incorporated into the operation. These isotopes are vital for Positron Emission Tomography (PET) scans, a non-invasive imaging technique widely used to diagnose and monitor various cancers.

PET scans allow doctors to visualize metabolic activity within the body, aiding in early detection and treatment planning. HIT's facility will focus on producing Fluorine-18 (F-18), a key isotope used in the most common PET imaging drug, Fluorodeoxyglucose (FDG). HIT anticipates commencing production of FDG by the end of the current year, which is expected to reduce reliance on overseas suppliers and improve access to these critical imaging agents for hospitals and clinics across the region and potentially beyond.